CGRP inhibitors provide new options for migraine treatment

Based on that research, the U.S. Food and Drug Administration (FDA) has approved two different types of migraine therapies targeting CGRP.  The first CRGP inhibitors were designed as preventive therapy to reduce both the frequency and severity of migraine attacks. Since then, the FDA has also approved drugs to help stop or greatly reduce the symptoms of an acute headache. Here's what you should know if you're considering trying CGRP inhibitors.